World-Pharmacists-Day-Insert
X

Find Approved Oncology Drugs in Clinical Development in AUSTRALIA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Neratinib Maleate

            Therapeutic Area: Oncology Product Name: Nerlynx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 17, 2020

            Details:

            NERLYNX significantly reduce the ongoing risk of recurrence in HER2+ early breast cancer patients with the greatest benefit seen in women who are also HR+and who commence therapy within 12 months of completing trastuzumab-based therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tisagenlecleucel

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 28, 2020

            Details:

            Novartis has entered into an agreement with Cell Therapies to manufacture Kymriah at their production facility within the Peter MacCallum Cancer Centre in Melbourne.